⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27610181 | 0.90 | ATM (0.61) | — | |
| SCHEMBL7437809 | 0.86 | ATM (0.58) | — | |
| SCHEMBL4826043 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL14743836 | 0.81 | — | — | |
| SCHEMBL146802 | 0.79 | — | — | |
| SCHEMBL146803 | 0.79 | — | — | |
| SCHEMBL145144 | 0.79 | — | — | |
| SCHEMBL5803747 | 0.74 | — | — | |
| SCHEMBL10802281 | 0.73 | — | — | |
| SCHEMBL19930552 | 0.73 | NUDT1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-7465728-B2 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |